MacKenzie Fiona M, Milne Kathleen E, Gould Ian M
Medical Microbiology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, Scotland, UK.
Int J Antimicrob Agents. 2004 Apr;23(4):337-42. doi: 10.1016/j.ijantimicag.2003.09.019.
Discrepancies between proven clinical success of cefaclor and its relatively poor activity in vitro were investigated against eight pneumococcal isolates. The bacteriostatic minimum inhibitory concentration (MIC) (the concentration resulting in no growth/kill relative to the starting inoculum) was derived from time kill studies. Bioassay results demonstrated an in vitro half-life of >24 and 9 h for cefuroxime and cefaclor, respectively. The mean NCCLS MIC for cefaclor was 1.4 and 0.3 mg/l for cefuroxime. The corresponding mean bacteriostatic MICs were 0.24 and 0.16 mg/l. Whilst cefaclor NCCLS MICs were significantly higher compared with cefuroxime MICs (P = 0.00058) there was no statistical differences between the bacteriostatic MICs (P = 0.259). Bacteriostatic MIC determination established that cefaclor and cefuroxime are equally active against pneumococci.
针对8株肺炎球菌分离株，研究了头孢克洛已证实的临床疗效与其相对较差的体外活性之间的差异。抑菌最低抑菌浓度（MIC）（相对于起始接种量导致无生长/杀灭的浓度）来自时间杀菌研究。生物测定结果表明，头孢呋辛和头孢克洛的体外半衰期分别>24小时和9小时。头孢克洛的平均NCCLS MIC为1.4mg/l，头孢呋辛为0.3mg/l。相应的平均抑菌MIC分别为0.24mg/l和0.16mg/l。虽然头孢克洛的NCCLS MIC显著高于头孢呋辛的MIC（P = 0.00058），但抑菌MIC之间无统计学差异（P = 0.259）。抑菌MIC测定确定头孢克洛和头孢呋辛对肺炎球菌的活性相同。
